Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 614-406-6 | CAS number: 68308-61-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Effect on fertility: via oral route
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
Additional information
Reproduction/Developmental Toxicity Screening Test
The subject of this study was the Reproduction/Developmental Toxicity Screening Test with the test item GARDO TP10451 in the Rat according to OECD 421 and the draft OECD guidance document 43. The guideline is designed for use with the rat, which is the preferred rodent species for reproduction toxicity testing. The purpose of this study was to obtain initial information on the possible effects of the test item on reproduction and development when administered orally (by gavage) to CRL:(WI)BR rats at repeated doses of 50, 250, and 1000 mg/kg body weight/day (mg/kg bw/day) compared to control animals. As a screening test, it was intended to provide initial information on possible effects on male and female reproductive performance such as gonadal function, mating behaviour, conception, pregnancy, parturition as well as on development of the F1 offspring from conception to day 4 post-partum associated with administration of repeated doses. The dose setting was based on findings obtained in previous studies (previous rodent study: repeated dose range finding study with the test item in rats LAB study code 08/625-100PE), and in agreement with the Sponsor. Doses were selected with the aim of inducing toxic effects but no death or suffering at the highest dose and a NOAEL at the lowest dose.
Stability and homogeneity of test item in the vehicle, PEG400, was analytically proven. Assessment of test item stability in this vehicle, in the conditions employed on the study indicated an up to 6 hr stability at room temperature, and 96 hr stability at 2-8°C, at concentrations from approximately 1 to 250 mg/mL in PEG400 formulations, with a recovery within the acceptable range of 100 ± 10% (104-94%). A separate analytical report provides this information. Analysis of dose formulation concentration and homogeneity was conducted during the study from all the concentrations employed; the formulations were homogenous, and the measured concentrations ranged from 102 to 109 % of nominal concentrations. The analytical results were considered suitable for the study purposes.
Animals were inspected for signs of morbidity and mortality twice daily (at the beginning and end of each day). Clinical observations for signs of ill health or reaction to treatment were made at least once daily, with detailed examination performed weekly. Special attention was paid to evaluation of the mating, pregnancy, parturition and post-partal periods, and relevant parameters and/or indices were measured and/or calculated. Body weight and food consumption were measured at least weekly. Gross necropsy was conducted at the end of the treatment period. The absolute and relative organ weights of selected organs and tissues were determined. A histopathological examination was performed on the selected preserved organs and tissues of the animals of the control and high dose groups, on the testes and epididymides of the low and mid dose males, and on abnormal tissues from low and mid dose groups.
Results and Conclusion
GARDO TP10451 administered daily by oral gavage in Wistar rats, for 28 days in the male animals, and up to 47 days (females), at dose levels of 50, 250 and 1000 mg/kg bw/day, did not result in any clinical changes that could be ascribed to the treatment.
No effects considered adverse, or toxicologically significant, were noted on the mean body weight, body weight gain, or food consumption values in the treated groups compared to control animals. Treatment related effects were observed in the body weight gain of females in the high dose group. These effects were nevertheless not regarded as adverse, taking into account the absence of other treatment related effects at this dose level.
There were no significant differences between the control and test item treated groups with regard to reproductive ability, or in the mating, fertility or gestation indices. Test item administration did not impact the duration of the mating period. Successful coitus (sperm positive vaginal smears and/or vaginal plugs) generally occurred within up to 8 days of pairing (cohabitation). No test item effect on the duration of pregnancy was observed. All females littered in 22 to 23 days. There were no abnormalities in pups that were ascribed to the treatment. All the parturitions were normal. There were no adverse effects, or biologically significant variations of the parameters related to pregnancy, parturition, or post-partal period noted in the treated groups at dose levels up to and including 1000 mg/kg bw/day compared to control animals. There were no test item-related alterations in the delivery data of GARDO TP10451 treated dams as compared to the control value. The number of corpora lutea and implantations were comparable or slightly higher in the treated groups up to and including 1000 mg/kg bw/day, compared to females in the control groups. Pre-implantation, intrauterine and total mortality values were lower in the high dose group administered 1000 mg/kg bw/day than in the control animals. Slightly higher values than control without attaining statistical significance were observed at 50 and 250 mg/kg bw/day; however, the differences were minor, and based on the lack of similar changes in the high dose group, these variations were neither considered toxicologically significant, nor related to test item administration.
Litter examination did not reveal any clinical, or macroscopic test item-related effects compared to observations noted in the control group. GARDO TP10451 administration had no adverse effect on the mean or total number of pups, or pup survival index. The sex ratio was similar in the control and treated groups, and no significant variations were observed on PN4 vs. PN0.
In the parent animals surviving to scheduled termination, the administration of GARDO TP10451 at dose levels of 50, 250 or 1000 mg/kg bw/day was not associated with any adverse test item-related macroscopic or microscopic findings. There were no treatment-related organ weight changes. Treatment related effects were observed in apoptosis parameters in the epididymides in males in the high dose group. These effects were nevertheless not regarded as adverse in the absence of an impairment of any reproductive performance parameters in the high dose group.
In conclusion, under the conditions of this study, a no observed effect level (NOEL) for parental effects (systemic) of 250 mg/kg bw/day was derived for GARDO TP10451 based on female body weight reductions and apoptosis in the epididymides of males in the high dose group. The no observed adverse effect level (NOAEL) for GARDO TP10451 for parental effects (systemic) was 1000 mg/kg bw/day based on the absence of toxicologically adverse effects up to and including the high dose level of both sexes. For reproduction parameters, no effects were noted at any dose level, resulting in a NOAEL of 1000 mg/kg bw/day. For pup growth rate and adverse effects, the NOAEL was 1000 mg/kg bw/day.
Short description of key information:
Under the conditions of a reproduction/developmental toxicity screening test (OECD 421), a no observed effect level (NOEL) for parental effects (systemic) of 250 mg/kg bw/day was derived for GARDO TP10451 based on female body weight reductions and apoptosis in the epididymides of males in the high dose group. The no observed adverse effect level (NOAEL) for GARDO TP10451 for parental effects (systemic) was 1000 mg/kg bw/day based on the absence of toxicologically adverse effects up to and including the high dose level of both sexes. For reproduction parameters, no effects were noted at any dose level, resulting in a NOAEL of 1000 mg/kg bw/day. For pup growth rate and adverse effects, the NOAEL was 1000 mg/kg bw/day.
Justification for classification or non-classification
Based on the results of the reproduction/developmental toxicicty screening test (no adverse effects up to 1000 mg/kg bw/day) GARDO TP10451 has not to be classified regarding reproduction/developmental toxicity according to CLP (GHS) and 67/548/EEC.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.